UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported):  February 4, 2019

Balchem Corporation
(Exact name of registrant as specified in its charter)

Maryland
1-13648
13-2578432
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

52 Sunrise Park Road, New Hampton, NY 10958
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (845) 326-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 4, 2019, Balchem Corporation (the “ Company ”) announced that Martin Bengtsson has been appointed Chief Financial Officer of the Company, effective immediately.

Martin Bengtsson, age 41, joins the Company from Honeywell International, where he served as Vice President and Chief Financial Officer for the Performance Materials and Technologies business unit from April 2018 until January 2019.  Prior to that, Mr. Bengtsson was Vice President and Chief Financial Officer for the following Honeywell business units: (i) Advanced Materials’ (August 2016 – April 2018), (ii) Specialty Products (March 2016 – August 2016), and (iii) Fluorine Products’ April 2014 – February 2016).  Prior to these roles, Mr. Bengtsson held a number of positions in Honeywell’s accounting and finance unit, each with increasing responsibility, including Vice President, Global Controller for the Performance Materials and Technologies business unit from October 2011 until March 2014 and as Vice President, Finance – Group Corporate Audit from February 2009 until September 2011.

The Company’s press release describing these events is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

In connection with the hiring of Mr. Bengtsson as Chief Financial Officer, the Company and Mr. Bengtsson have entered into an offer letter that outlines his responsibilities and compensation. The offer letter provides for a base salary of $435,000 and a one-time sign-on bonus of $171,000. The offer letter also provides that Mr. Bengtsson will be eligible to participate in the Company’s Long-Term Incentive Plan with a target award level of 100% of his base salary. Mr. Bengtsson will also receive 12,000 shares of Company restricted stock, which will vest ratably over three years after the date of grant, with one-third vesting each year beginning in 2020, and options to acquire15,000 shares of Company stock, which options will vest 20% after Year 1, 40% after Year 2, and 40% after Year 3.

The foregoing summary of the offer letter does not purport to be a complete description and is qualified in its entirety by reference to the full text of the offer letter, which is filed as Exhibit 10.1 and incorporated herein by reference.

William Backus, who has served as interim Chief Financial Officer since October 2018, will return to his role as Chief Accounting Officer.

Item 9.01
Exhibits.

(d)
Exhibits .

Exhibit No.
Description

Offer Letter to Martin Bengtsson dated January 10, 2019

Press Release dated February 4, 2019


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BALCHEM CORPORATION
   
 
By:/s/ Mark Stach
 
Mark Stach, General Counsel and Secretary
   
Dated: February 4,  2019
 




EXHIBIT 10.1

January 10, 2019

Martin Bengtsson
9 Barnsdale Road
Madison, NJ

Dear Martin:

I am pleased to make the following offer to you for the position of Chief Financial Officer with Balchem Corporation (“Balchem” or the “Company”) a compensation package as described below:

Annual base salary:
$ 435,000

Date of Hire:
February 4, 2019

·
Incentive Compensation:   You will also be eligible to participate in the Balchem Corporation Incentive Compensation Program (ICP).  Incentive goals will be designed annually with a target bonus equal to 55% of your actual base salary earned during the applicable performance year.

·
Signing Bonus :  On your date of hire, you will receive 12,000 Restricted Shares of Balchem stock; 15,000 Non-Qualified Stock Options as well as a one-time cash bonus payment of $171,000 , payable with your first paycheck with the Company.

*The Restricted Shares will vest ratably over three years with one-third (4,000 Shares) vesting each year beginning in 2020.  The Stock Options will vest ratably over three years (20% after 1 year, 40% after 2 years, 40% after 3 years).

·
Long-Term Incentive Plan (LTIP):  You will also be eligible to participate in Balchem’s Long Term Incentive Program (“ LTI ”), which provides for incentive compensation in the form of equity of Balchem, based upon achieving certain performance objectives defined annually, and similarly based upon the authorization of the Balchem’s Board of Directors or an authorized committee thereof.  Under the LTI, you may earn a Target Award of up to 100% of your Base Salary in Balchem stock options, time-based Restricted Shares and Performance Award Restricted Shares (valued on the grant date) and in certain circumstances of performance, amounts exceeding the Target Award, subject to parameters defined in, and the terms and conditions of, the LTI, a copy of which will be provided to you.

·
401 (k): You will be eligible to participate in the 401(k) plan on the first day of the month following 60 calendar days of employment.  Employees can contribute up to the 2019 annual IRS limit of $19,000. If you are 50 years of age or older, (or if you will reach age 50 by the end of the year), you may make a catch-up contribution of up to $6,000 in addition to the normal IRS annual limit. The Company matches 100% on the first 6% of your compensation that you 


contribute to the plan .  Effective, 1/1/18, all new employees will be automatically enrolled in the 401K with a 6% contribution and will have the option to change the percentage or opt-out upon eligibility.

·
Vehicle Allowance Balchem will provide you with a $900 per month vehicle allowance.  The allowance will be included in your regular pay process each month.  Additionally, you will be reimbursed for your business mileage at the rate determined by Balchem, which is subject to change.

·
Vacation / Time-Off Benefits:   You will be entitled to 160 hours of vacation, prorated during your first year of employment.  Sabbatical days are earned after one year of employment at the rate of one day per quarter.  Other portions of the paid time off plan include holidays and personal time, as described in the Summary of Benefits (a copy of which will be provided to you).

·
Group Medical and Dental insurance:    Participation in the group insurance plan is optional and it is a contributory plan.  You will be eligible to participate in the group insurance plan on the first day of the month following 60 calendar days of employment, with dependent coverage and eligibility as applicable.

·
COBRA:  Following any continuation/separation agreements with your previous employer, Balchem will reimburse your COBRA premium (you must submit proof of payment and the COBRA notice) for the period prior to your enrollment eligibility for the group insurance plans described above.  The reimbursement will be processed through payroll.
      
·
Business and Travel Insurance:   You will be provided with business travel accident insurance equal to five times annual salary to a maximum of $500,000;

·
Non-contributory life insurance with accidental death and dismemberment : equal to one times your base salary, whether or not you participate in the group health or dental programs;

·
Long Term Disability (LTD):   Eligible on the first day of the month following one year of employment, this plan provides 60% of basic monthly earnings before taxes up to a maximum of $15,000 if you become totally disabled, as described in the Summary of Benefits.

·
Additional benefits include:   Short Term Disability, EAP, Educational Reimbursement, Contributory Supplemental Life, with detail and eligibility requirements as described in the Summary of Benefits.

·
Severance:   In the event Company terminates the employment of Employee for any reason other than (i) “ Cause ” (as defined below), (ii) Employee’s death, or (iii) by reason of notice from Employee that Employee intends to terminate his employment with Company, and subject to Employee’s compliance with [Confidentiality/Non-Compete] and Employee’s execution of a full and completed waiver release of claims in favor of Company, its affiliates and their respective


officers and directors, (the “Release”) and such Release becoming effective and irrevocable on a date (the “Release Effective Date”) no later than sixty (60) days following Employee’s date of termination, and Employee shall be entitled to receive as his sole and exclusive remedy and compensation by reason of or arising out of such termination, an amount (the “Severance Amount”) equal to one (1) year of annual base salary.  The Severance Amount shall be due and payable to Employee in twelve (12) equal monthly installments commencing with the month following the month of such termination; provided, however, that any installments otherwise payable prior to the Release Effective Date shall instead be paid with the installment due for the month following the Release Effective Date.

Cause ” as used herein shall mean the following:

1)
Excessive absence or lateness;

2)
Gross insubordination or material violation of published Company policies;

3)
Failure devote Employee’s full-time efforts the Company’s business;

4)
Failure to comply with any regarding the protection of Company information and confidentiality; or

5)
Any job-related action which constitutes a violation of any applicable criminal statute.

In addition to this offer letter we have enclosed a copy of Balchem’s Confidentiality and Non-Competition Agreement,   Substance Abuse Policy for Applicants/Employees , and Summary of Benefits for your review.  If acceptable, sign the letter and return to us, along with a signed copy of the Confidentiality and Non-Competition Agreement and the Receipt of Substance Abuse Policy for Applicant/Employees form, both, which are requirements of employment with Balchem.  You can return all documents via scan/e-mail to btignor@balchem.com or to the following address:

 
Balchem Corporation
 
52 Sunrise Park Road
 
New Hampton, NY  10958
 
Attn: Brent Tignor

Once the signed acceptance agreement is received, you can go for your drug screen.  You just need to bring the attached Collection Authorization Form (labcorp.doc) with you.  Employment is contingent upon a negative intoxicant screen, pre-employment physical if applicable, and successful background check.  For the background check, you will receive a separate e-mail from Shield Screening, providing a link directing you to complete an authorization form.   After all are successfully completed and a start date is determined, you will receive another e-mail directing you to begin the electronic on-boarding process, for which all sections must be completed prior to your first day.

I look forward to your acceptance of this offer and to welcoming you to Balchem Corporation.  If you have any questions about this offer, please do not hesitate to call me directly at (845) 326-5663.  We are excited to have you on the Team!


Sincerely,
Brent Tignor
Vice President Human Resources

Disclaimer:  Nothing in this offer is intended to be, nor should it be, construed as a guarantee that employment or any benefit will be continued for any period of time.  Employment is “at-will;” meaning that you have the right to terminate your employment at any time, with or without cause or notice, and the Company has the same right.     Employment is contingent upon a negative drug screen, satisfactory completion of a job-related physical examination, satisfactory findings of any subsequent background or reference investigation and upon execution of the Balchem Corporation Confidentiality and Non-Competition Agreement.

 
Accepted by:
 
   
Martin Bengtsson
   
Date




EXHIBIT 99.1

NEW HAMPTON, NY – February 4, 2019  Balchem Corporation (NASDAQ: BCPC) announced today the appointment of Martin Bengtsson as Chief Financial Officer (CFO), effective immediately.  Mr. Bengtsson will report directly to Theodore L. Harris, President, Chief Executive Officer, and Chairman.

Mr. Bengtsson joins Balchem following a successful 15-year career at Honeywell, Inc.  Martin progressed through a variety of finance, accounting, and audit positions at Honeywell including Vice President, Finance – Group Corporate Audit; Vice President, Global Controller – Performance Materials & Technologies; and several division CFO roles, including his most recent role as CFO, Performance Materials & Technologies.

“As an experienced executive, Martin’s strategic capabilities and business acumen along with his finance, accounting, and control expertise will contribute significantly to our company,” said Harris.  “Martin will be an excellent addition to the Balchem team and I look forward to partnering with him as we continue to execute against our strategic priorities while delivering strong financial performance.”

Mr. Bengtsson earned a Bachelor of Arts degree in Economics from Northwestern University and began his career as a Senior Auditor for Deloitte prior to joining Honeywell, Inc.

“This is a very exciting time to join Balchem, a company with a proven track record and strong balance sheet that is strategically well positioned in growth markets.  I’m thrilled at the opportunity to partner with Ted and the entire leadership team to drive the company forward.” said Bengtsson.

About Balchem Corporation
Balchem Corporation reports four business segments: Human Nutrition & Health; Animal Nutrition & Health; Specialty Products; and Industrial Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. The Industrial Products segment manufactures and supplies certain derivative products into industrial applications.

Forward-Looking Statements
This release contains forward-looking statements, which reflect Balchem’s expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem’s expectations, including risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31, 2017. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date.